FDAnews
www.fdanews.com/articles/61341-ym-biosciences-licenses-monoclonal-antibody-nimotuzumab-to-daiichi-pharmaceutical-for-japan

YM BIOSCIENCES LICENSES MONOCLONAL ANTIBODY, NIMOTUZUMAB, TO DAIICHI PHARMACEUTICAL FOR JAPAN

August 1, 2006

YM BioSciences Inc., a company engaged in the acquisition, development and commercialization of oncology and acute care products, announced that its majority owned subsidiary, CIMYM BioSciences Inc., has licensed development and marketing rights in Japan for its anti-EGFR humanized antibody, nimotuzumab, to Daiichi Pharmaceutical Co., Ltd. (a wholly owned subsidiary of DAIICHI SANKYO COMPANY, LIMITED, one of Japan's largest pharmaceutical companies).

BioSpace (http://www.biospace.com/news_story.aspx?StoryID=25805&full=1)